TNFα program

About DeepCure

DeepCure is a private, preclinical-stage biotech applying a proprietary AI/ML and physics-integrated platform to drug difficult targets in immunology. The company has identified its first two development candidates: DC-9476, an oral BRD4-BD2 inhibitor for rheumatoid arthritis and related conditions, and DC-15442, an oral STAT6 inhibitor for asthma and atopic dermatitis, both in IND-enabling studies. With a leadership team combining deep AI expertise from MIT with seasoned drug development experience from major pharma, DeepCure aims to create a new class of oral therapies for diseases dominated by injectable biologics.

Therapeutic Areas